Female GH Optimization
85
sintesi
2
2,200
intermediate
May 17, 2026
Panoramica
The Female GH Optimization stack pairs Ipamorelin with Tesamorelin specifically because these two peptides offer the most favorable side-effect profile for women seeking growth hormone benefits without androgenic or metabolic complications. Tesamorelin is a 44-amino-acid GHRH analog that is the only peptide in this category with full FDA approval (marketed as Egrifta for HIV-associated lipodystrophy). It stimulates pituitary GH production through the GHRH receptor, producing physiological GH pulses that closely mimic natural secretion patterns. Women naturally produce more GH than men (approximately 2x the daily output) but experience a sharper decline with age, making GH optimization particularly impactful for female physiology. Tesamorelin has been shown in clinical trials to reduce visceral adipose tissue by 15-20% without affecting subcutaneous fat — making it uniquely suited for the central adiposity pattern common in perimenopause and menopause. Its effects on IGF-1 are modest and predictable, staying within physiological ranges. Ipamorelin complements Tesamorelin by adding ghrelin-pathway stimulation without the appetite increase, cortisol elevation, or prolactin changes seen with other GH secretagogues. For women, the absence of prolactin effects is particularly important as elevated prolactin can disrupt menstrual cycles and breast tissue. The combination produces amplified GH pulses (via GHRH + GHS synergy) while maintaining clean hormonal profiles. Benefits typically observed include improved skin elasticity and thickness, reduced visceral fat, better sleep architecture, improved bone mineral density markers, and enhanced recovery from exercise. This stack is well-suited for women over 35 seeking comprehensive anti-aging and body composition benefits.
Protocollo di Dosaggio
200 mcg
per dose
2,000 mcg
per dose
Obiettivi & Evidenze
Avvertenze
- Tesamorelin is FDA-approved (Egrifta) for HIV lipodystrophy. Off-label use for anti-aging is common but not approved. Ipamorelin remains FDA Category 2 (restricted) as of July 2026.
Comments
Sign in to join the discussion
Avvertenza: Questo stack è compilato dalla comunità e a scopo di ricerca solo. Peptide Contacts non verifica la sicurezza o l'efficacia dei stack compilati. Consulta sempre un professionista sanitario qualificato prima di utilizzare qualsiasi protocollo di peptidi.